The International Lymphoma Radiation Oncology Group (ILROG) laid out a set of emergency recommendations for patients with hematologic malignancies to manage increased demand during the coronavirus disease 2019 (COVID-19) pandemic.1
The focus of the recommendations is for alternative radiation treatment schemes, with an emphasis on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. Moreover, the guidance was informed by adherence to acceptable radiobiological parameters and clinical tolerability.
“This important paper by ILROG provides an excellent example of how the medical community is coming together to create cohesive strategies to adapt treatment in the setting of COVID-19 in order to maintain quality care, while lowering toxicity, minimizing viral exposure risk, and decreasing resource utilization,”…
